Business Wire Industry News

Wednesday, August 5, 2020

Zymeworks Reports 2020 Second Quarter Financial Results

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the quarter ended June 30, 2020. “Among many notable accomplishments in the past quarter, I am particularly excited about the transition of our lead therapeutic program, zanidatamab, into late stage clinical development, providing a clear path for Zymeworks to seek its first potential approval in bi

Wednesday, August 5, 2020

VBI Vaccines Awarded Up to CAD$56 Million Contribution from Canadian Government to Accelerate Coronavirus Vaccine Development

OTTAWA, Ontario & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--Variation Biotechnologies Inc., an Ottawa-based wholly-owned Canadian subsidiary of VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has been awarded up to a CAD$56 million contribution from the Strategic Innovation Fund of the Government of Canada to support the development of the company’s coronavirus progr

Wednesday, August 5, 2020

Versant Ventures Launches Matterhorn Biosciences

BASEL, Switzerland--(BUSINESS WIRE)--Versant Ventures today announced the debut of Matterhorn Biosciences AG, a biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that recognize and kill a wide range of tumors of various tissue origins. Versant has made a $30 million commitment to the new company, which was founded by pioneers in the MR1 field at the University of Basel. It is the most recent company to be launched out of Versant’s Ridgeline D

Wednesday, August 5, 2020

IMV Receives Funding From Canadian Governmental Agencies for COVID-19 Vaccine Phase 1 Clinical Study

DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that Canadian government agencies will contribute up to CA$4.75 million to advance Phase 1 clinical development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-COV-2. The Company is receiving CA$4.15 mi

Tuesday, August 4, 2020

MedX Health Corp. Announces Closing of Non-Brokered Private Placement

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announces that further to the Conditional Approval from the TSX Venture Exchange for a non-brokered Private Placement to accredited investors of up to 16,666,666 units at $0.12 per unit (“Unit”), to raise up to $2,000,000, the closing of a first tranche of that placement has taken place on July 31, 2020, for a total of 2,600,000 units, raising a total of $312,000. Each Unit is comprised of One (1) fu

Tuesday, August 4, 2020

LEO Pharma Announces U.S. Food and Drug Administration Fast Track Designation for delgocitinib Cream for the Treatment of Adults With Moderate-to-severe Chronic Hand Eczema

BALLERUP, Denmark & MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced that delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of adults with moderate-to-severe chronic hand eczema (CHE). There are currently no treatment options available in the U.S. specifically developed and approved for the treatm

Tuesday, August 4, 2020

ZYUS Life Sciences Receives Medical Sales License from Health Canada

SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Inc. ("ZYUS"), a next-generation life sciences company leading scientific research and development in phyto-therapeutics, is pleased to announce that effective July 31, 2020, it received its Health Canada Medical Sales License, marking another important step on the Company’s journey to improve patient outcomes in Canada and around the world. Launched in 2018 by Canadian medical cannabis pioneer Brent Zettl, ZYUS is on a mission to adv

Tuesday, August 4, 2020

Acerus to Report Second Quarter 2020 Financial Results and Host Investor Conference Call

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP; OTCQB:ASPCF) (“Acerus” or the “Company”) today announced that it will issue second quarter 2020 financial and operating results on Tuesday August 11, 2020 before the market opens. The Company will host an investor conference call that same day, August 11, at 10:00 a.m. Eastern Time, to discuss these results. To access the call live, please dial 416-406-0743 or 1-800-898-3989 and use access code 1116365#. Listeners are encour

Tuesday, August 4, 2020

Infusion Biosciences Announces First Commercial Launch of Hemp-Derived Infuz2O Beverage in The U.S. With Whole Plant Extractions and Kalo

TORONTO--(BUSINESS WIRE)--Infusion Biosciences Inc. (“Infusion Biosciences”), a biotechnology company focused on discovering and commercializing innovative hemp and cannabis products, is pleased to announce the first commercial launch of a beverage utilizing its proprietary water-soluble hemp extract ingredient Infuz2O in the United States with KALO (www.drinkkalo.com) (the “Infuz2O Beverage Launch”). The KALO line of beverages is being serviced via a supply agreement with Whole Plant Extractio

Tuesday, August 4, 2020

Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Monday, August 10, 2020 at 11:00 a.m. EDT. In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporat

Friday, July 31, 2020

VBI Vaccines Announces Second Quarter 2020 Financial Results and Provides Corporate Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported financial results for the second quarter ending June 30, 2020 and provided a corporate update. Jeff Baxter, President and CEO, commented: “The second quarter of 2020 was again a time of unprecedented disruption, with the COVID-19 pandemic continuing to have severe global public health, s

Thursday, July 30, 2020

Devonian Announces Correction to Press Release Issued July 28, 2020

QUEBEC--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announces today that a correction had to be made to the press release issued on July 28, 2020, concerning the granting of stock options: Stock Option Grants On July 28, 2020, the Corporation announced that the Board of Directors had approved stock

Thursday, July 30, 2020

GC Pharma Reports Q2 2020 Results

YONGIN, South Korea--(BUSINESS WIRE)--GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for second quarter of 2020. Second-Quarter Reported Results(1) Key Figures(1) Q2 2020 Growth(2) Total revenues KRW 360.0 billion +1.1% Operating profit KRW 15.6 billion -22.0% K-IFRS profit after taxation KRW 13.6 billion T/P (1) Results from continuing operations (Green Cross MS’ blood bag b

Thursday, July 30, 2020

Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020

VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the markets close. Aurinia’s executive team will host a conference call to discuss the Company’s financial results and to provide a general business update. The conference call and webcast is scheduled for 4:30 pm EDT on August 11, 2020. In order to participate in the

Thursday, July 30, 2020

Ipsen Presents Its Half Year 2020 Results and Reinstates Guidance for Full Year 2020

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first half of 2020. Resilient H1 financial performance: Group sales growth of 3.1% as reported and at constant currency, driven by Specialty Care sales growth of 5.9%1, led by Somatuline® (lanreotide) (up 16.4%1). Consumer Healthcare sales were down 21.1%1. Q2 2020 Group sales decreased by 2.2%1, adversely impacted by COVID-19.